Home › Funds › Ikarian Capital, LLC › PHVS
Ikarian Capital, LLC position in PHVS
PHARVARIS N V · Health Care
Ikarian Capital, LLC reported holding 502,372 shares of PHVS (PHARVARIS N V) in its Q3 2026 13F filing — a position valued at US$15.9M, representing 2.34% of its reported portfolio and ranking #8 among its reported holdings. Ikarian Capital, LLC has disclosed PHVS holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's PHVS position evolved
Ikarian Capital, LLC first disclosed a stake in PHVS in Q3 2025 at 210,165 shares (US$5.2M). The position peaked in Q3 2026 at 502,372 shares, worth US$15.9M. Across 5 filings, Ikarian Capital, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 502,372 shares valued at US$15.9M — an increase of 193,516 shares quarter over quarter.. Notable position changes include a 132% increase in Q4 2025 (shares rose 2% over the following quarter), a 37% trim in Q2 2026 (shares fell 8% over the following quarter), a 63% increase in Q3 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 210.16K | $5.24M | New |
| Q4 2025 | 486.86K | $13.51M | Add |
| Q1 2026 | 486.86K | $13.75M | Hold |
| Q2 2026 | 308.86K | $10.68M | Reduce |
| Q3 2026 | 502.37K | $15.94M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHVS and 13F data
PHVS (PHARVARIS N V) is a Health Care company. 47 other funds we track also report a position in PHVS — the largest reported positions include Foresite Capital Management IV, LLC (US$151.6M), venBio Partners LLC (US$141.4M), EQT Fund Management S.a r.l. (US$108.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHVS
- Foresite Capital Management IV, LLC 4.78M sh · $151.58M · Q3 2026
- venBio Partners LLC 4.46M sh · $141.44M · Q3 2026
- EQT Fund Management S.a r.l. 3.42M sh · $108.63M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 2.59M sh · $82.15M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 2.48M sh · $76.92M · Q3 2026
- GENERAL ATLANTIC, L.P. 1.65M sh · $52.39M · Q3 2026
- Saturn V Capital Management LP 1.39M sh · $44.22M · Q3 2026
- Novo Holdings A/S 1.02M sh · $32.34M · Q3 2026
- Jones Hill Capital LP 987.64K sh · $31.33M · Q3 2026
- TCG Crossover Management, LLC 947.54K sh · $30.06M · Q3 2026
- Commodore Capital LP 925.00K sh · $29.34M · Q3 2026
- Tetragon Partners GP Ltd 838.25K sh · $26.59M · Q3 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held PHVS?
Ikarian Capital, LLC has disclosed PHVS holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Ikarian Capital, LLC's current position in PHVS?
As of Q3 2026, Ikarian Capital, LLC holds 502.37K shares of PHVS (PHARVARIS N V), valued at $15.94M, representing 2.34% of its reported portfolio and ranking #8.
Has Ikarian Capital, LLC been buying or selling PHVS?
In the latest 13F filing (Q3 2026), Ikarian Capital, LLC increased its position in PHVS. The position peaked in Q3 2026 at 502.37K shares.
Which other funds hold PHVS?
Other major institutional holders of PHVS include Foresite Capital Management IV, LLC, venBio Partners LLC, EQT Fund Management S.a r.l., among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.